SEARCH

SEARCH BY CITATION

Keywords:

  • Enterococcus faecium;
  • ampicillin resistance;
  • vancomycin resistance;
  • virulence;
  • clinical epidemiology;
  • molecular typing methods

Abstract

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

For many years, Enterococcus faecium was considered to be a commensal of the digestive tract, which only sporadically caused opportunistic infections in severely ill patients. Over the last two decades, vancomycin-resistant E. faecium (VREF) has emerged worldwide as an important cause of nosocomial infections, especially in immunocompromised patients. The global Vancomycin-resistant enterococci (VRE) epidemic was preceded by the emergence of ampicillin-resistant E. faecium (AREfm) in the United States in the early 1980s, followed by the rapid emergence of VRE in the 1990s. A similar increase of VRE may occur in countries with still low levels of VRE in hospitals (such as The Netherlands), but increasing incidence of AREfm infections. Molecular epidemiological studies of both human- and animal-derived E. faecium isolates using multilocus sequence typing revealed the existence of host-specific genogroups, including a specific genetic lineage designated CC17, associated with hospital-related isolates. These strains were characterized by ampicillin and quinolone resistance. In addition, the majority of these CC17 isolates contain over hundred hospital-clade-specific genes, including mobile elements, phage genes and plasmid sequences, hypothetical and membrane proteins and antibiotic and regulatory genes and a putative pathogenicity island including the esp gene.


General

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

Enterococci are widespread in nature and are commonly found in alimentary tracts of humans and other animals as well as in soil, water and food. In human adults, enterococci account for 1% of the intestinal microflora (Sghir et al., 2000). Enterococci are facultative anaerobic, catalase-negative Gram-positive cocci that occur singly, in pairs or as short chains. The optimum growth temperature is at 35 °C, but the growth temperature can range from 10 to 45 °C (Facklam & Collins, 1989). Furthermore, enterococci are able to survive extreme temperature and chemical disinfectants like chlorine, glutaraldehyde and alcohol, which is an important characteristic for their survival and spread in hospitals (Freeman et al., 1994; Kearns et al., 1995; Bradley & Fraise, 1996). All enterococci grow in broth containing 6.5% NaCl and hydrolyze esculin in the presence of 40% bile salts (bile–esculin medium) (Facklam & Collins, 1989). Among the enterococcal species, Enterococcus faecalis and Enterococcus faecium are the most commonly encountered species in human feces (Noble, 1978; Murray, 1990). Although for years enterococci were for years considered to be harmless inhabitants of the gut flora, they are now among the leading causes of nosocomial infections of humans. Originally, the majority of clinical infections like bacteremia, endocarditis, urinary tract and surgical wound infections were caused by E. faecalis (80–90%), while E. faecium was found much less frequently (isolated in almost 10% of the infections) (Ruoff et al., 1990; Gordon et al., 1992; Jones et al., 1995; Patterson et al., 1995; Low et al., 2001). However, the ratio E. faecalis to E. faecium infections changed in favor of E. faecium in the United States in the late 1990s (Oppenheim, 1998; Mundy et al., 2000; Treitman et al., 2005), while in Europe the first reports on increased infections due to E. faecium were published in the mid-1990s (Torell et al., 1999; Fortun et al., 2002; Simonsen et al., 2003; Thouverez & Talon, 2004; Klare et al., 2005). Other enterococcal species that occasionally cause infections in humans are Enterococcus durans, Enterococcus avium, Enterococcus casseliflavus, Enterococcus hirae, Enterococcus gallinarum, Enterococcus raffinosus and Enterococcus muntdii (Murray, 1990; Ruoff et al., 1990; Gordon et al., 1992).

Antimicrobial resistance in enterococci

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

Antimicrobial resistance in enterococci can be divided into two classes: intrinsic resistance and acquired resistance (Table 1). Intrinsic resistance is due to either lack of target sites for the antimicrobial drug or insufficient penetration of the drug to the intracellular target site. For example, enterococci do not possess penicillin-binding proteins (PBPs), which bind cephalosporins with high affinity (Georgopapadakou & Liu, 1980; Neu, 1987), and as a result of poor permeability of the enterococcal cell wall, aminoglycosides are unable to reach their target site, although the combination of aminoglycosides and cell-wall synthesis inhibitors, like β-lactam antimicrobials and glycopeptides, has a synergistic killing effect on enterococci (Moellering Jr & Weinberg, 1971). Enterococcus faecium strains contain the gene aac(6)-Ii encoding the enzyme AAC(6′)Ii, which eliminates the synergism between cell-wall inhibitors and aminoglycosides like kanamycin, netilmycin and tobramycin. Gentamicin, however, is not affected by this enzyme (Costa et al., 1993). More important in the emergence of resistance is the ability of enterococci to acquire resistance through either chromosomal mutations or genetic exchange of mobile elements like transposons or plasmids (Witte et al., 1999). For example, mutations in the DNA gyrase or topoisomerase genes reduce the affinity of quinolones for these genes (Tankovic et al., 1996). In E. faecalis and E. faecium, many different transposons and plasmids have been identified conferring resistance to a wide variety of antimicrobial drugs, including erythromycin, gentamicin, kanamycin, streptomycin, tetracycline and vancomycin (Weaver et al., 2002). These resistance genes are present in combinations on large composite elements or as single genes. It has been hypothesized that E. faecium plays a central role in the acquisition, conservation and transfer of antimicrobial resistance genes among bacteria (Witte, 2004).

Table 1.   Antimicrobial susceptibility of enterococci
 AntibioticSpeciesMechanism of resistance
Intrinsic resistanceβ-LactamsAll enterococciLow affinity penicillin-binding proteins (PBP)
Penicillins (low level)  
Carbepenems (moderate level)  
Cephalosporins (high level)  
Aminoglycosides (low level)All enterococciInefficient uptake
Aminoglycosides (moderate level)E. faeciumProduction of chromosomal AAC(6′)Ii enzyme
Lincosamides and streptogramins AE. faecalis, E. avium, E. gallinarum, E. casseliflavusPutative efflux
Glycopeptides (low level)E. gallinarum, E. casseliflavusProduction of d-Ala-d-Ser ending peptidoglycan precursors
   
Acquired resistanceAmpicillin (high level)E. faecium, E. hiraeOverproduction or alterations of PBP5
 E. faecalisβ-lactamase (rare)
Aminoglycosides (high level)E. faecalis, E. faecium, E. gallinarum, E. casseliflavusAminoglycosides modifying enzymes e.g. AAC(6′)-APH (2″)
MacrolidesMost enterococciRibosomal methylation
ChloramphenicolE. faecium, E. faecalisCAT encoding enzymes
TetracyclineE. faecium, E. faecalisModification of ribosome protein
QuinolonesE. faecium, E. faecalisAlterations in DNA gyrase and Topoisomerase IV
Glycopeptides (high level)E. faecium, E. faecalisPrecursor modification
OxazolidinonesE. faeciumMutation in 23S rRNA gene

Ampicillin resistance

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

Enterococci are intrinsically resistant to β-lactam antimicrobials due to the low affinity of their PBP to β-lactam agents (Table 1) (Williamson et al., 1985; Fontana et al., 1992; Kak & Chow, 2002). They possess at least five and sometimes more than nine different PBPs (Williamson et al., 1986). The level of intrinsic resistance differs among the β-lactam antimicrobials. Generally, penicillins (e.g. ampicillin) have the highest activity, carbapenems slightly lower and cephalosporins have the lowest activity (Murray, 1990; Kak & Chow, 2002). Except for a few β-lactamase-producing E. faecalis isolates identified in the US (Murray et al., 1986, 1988; Murray, 1990), high-level ampicillin resistance is mainly found in E. faecium isolates derived from clinical specimens. High-level ampicillin resistance in E. faecium is due to either alterations by mutations in PBP5 resulting in even lower affinity for ampicillin (Al Obeid et al., 1990; Ligozzi et al., 1996; Zorzi et al., 1996; Rybkine et al., 1998) or by overproduction of PBP5 (Klare et al., 1992; Fontana et al., 1994; Zorzi et al., 1996). In 2000, a novel mechanism of β-lactam resistance has been described in a laboratory mutant of E. faecium not involving PBPs (Mainardi et al., 2000). In this strain, cross-linking during cell-wall elongation occurred by an ld-transpeptidation, which bypasses the usual β-lactam-susceptible dd-transpeptidation (Mainardi et al., 2000, 2002). So far, no clinical isolates with this type of resistance have been reported.

Glycopeptide resistance

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

Vancomycin, as well as teicoplanin, belong to the group of glycopeptide antimicrobials. These antimicrobials bind with high affinity to the d-alanyl-d-alanine (d-Ala-d-Ala) C-terminus of peptidoglycan pentapeptide precursors and block the addition of pentapeptide precursors by transglycosylation to the nascent peptidoglycan chain, thereby preventing subsequent cross-linking catalyzed by transpeptidation (Barna & Williams, 1984; Reynolds, 1989).

At present, six types of vancomycin resistance have been described in enterococci [Table 2, adapted from Courvalin (2006)]. Of the six phenotypes, the VanA and VanB types of glycopeptide resistance are reported most frequently (Coque et al., 1996; Sahm et al., 1999; Rice, 2006). Sequencing and functional analysis of the genes encoded by vanA and vanB gene clusters revealed that glycopeptide resistance is due to enzymes that encode for (1) synthesis of low-affinity precursors, in which the C-terminal d-Ala residue is replaced by d-lactate (d-Lac) or d-serine (d-Ser), thus modifying the vancomycin-binding target, and (2) for elimination of the high-affinity precursors that are normally produced by the host, thus removing the vancomycin-binding target (Brisson-Noel et al., 1990; Arthur et al., 1993, 1996; Reynolds & Courvalin, 2005).

Table 2.   Level and type of resistance to vancomycin in enterococci*
ResistanceAcquiredIntrinsic
High levelVariable levelModerate levelLow levelLow level
  • *

    Adapted from Courvalin (2006)

Type MIC (mg L−1)VanAVanB1/B2/B3VanDVanEVanGVanC1/C2/C3
Vancomycin64–10004–100064–1288–32162–32
Teicoplanin16–5120.5–14–640.50.50.5–1
ConjugationPositivePositiveNegativeNegativePositiveNegative
Mobile elementTn1546Tn1547UnknownUnknownUnknownNot applicable
 Tn1549-Tn5382    
SpeciesE. faeciumE. faeciumE. faeciumE. faecalisE. faecalisE. gallinarum
E. faecalisE. faecalisE. faecalis  E. casseliflavus
E. gallinarumS. bovis   E. flavescens
E. casseliflavus     
E. avium     
E. durans     
E. mundtii     
E. raffinosus     
S. aureus     
ExpressionInducibleInducibleConstitutiveInducibleInducibleConstitutive, Inducible
LocationPlasmid, chromosomePlasmid, chromosomechromosomechromosomechromosomechromosome
Modified targetd-Ala-d-Lacd-Ala-d-Lacd-Ala-d-Lacd-Ala-d-Serd-Ala-d-Serd-Ala-d-Ser

The first clinical isolates of vancomycin-resistant enterococci (VRE, both E. faecium and E. faecalis) were detected in Europe in 1986 (Leclercq et al., 1988; Uttley et al., 1988). Since then, VRE have spread rapidly all over the world. Especially in the US, VRE prevalence rates increased from 0% in 1989 to 28.5% in 2003 (Guru, 1993, 2004). Consequently, in the early 1990s, VRE were already the second most common nosocomial pathogen in the US (Frieden et al., 1993) and became endemic in many hospitals (Murray, 2000). In Europe, VRE prevalence rates in hospitals have been increasing since the year 2000 (Schouten et al., 2000; EARSS, 2004).

In 1988, French researchers discovered that glycopeptide resistance was plasmid-mediated (Leclercq et al., 1988). A few years later, the same group identified that vancomycin resistance was located on a small mobile genetic element designated transposon Tn1546, encoding the VanA phenotype (Arthur et al., 1993). Tn1546 belongs to the Tn3 family of transposons, which do not encode conjugative functions, and therefore dissemination of the transposon can only occur after integration into transferable elements such as plasmids and conjugative transposons (Arthur et al., 1993; Weaver et al., 2002). Furthermore, the same year, a second phenotype, VanB, was identified on a different mobile element, designated transposon Tn1547 (Quintiliani Jr et al., 1993). Based on nucleotide sequence differences in the vanB ligase gene, the vanB gene cluster can be subdivided into three subtypes, vanB1-3 (Patel et al., 1998; Dahl et al., 1999). The vanB2 gene cluster, the most frequently reported subtype worldwide, has been linked to the conjugative transposons Tn1549/Tn5382 (Carias et al., 1998; Dahl et al., 2000). A detailed overview of composite elements encoding antibiotic resistance in E. faecium and E. faecalis, including the vanA and vanB gene clusters, has been published in the book ‘Drug Resistance of Enterococci’ (Werner et al., 2006). Owing to these conjugative transposons and plasmids, dissemination of vancomycin resistance is not only the result of clonal expansion of resistant strains but also of horizontal gene transfer between strains and even species. Already at that time the potential transfer of these easily movable resistance genes to more pathogenic Gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA) was feared. At that time, vancomycin was the critically important antimicrobial to treat patients with MRSA infections. The first high-level vancomycin-resistant S. aureus (VRSA) was identified in Michigan (US) in 2002 (Chang et al., 2003). Up till now, five additional VRSA isolates have been identified (Appelbaum, 2006). In one case, a vancomycin-resistant E. faecalis was a likely source of the vanA gene cluster (Weigel et al., 2003), while VRSA may have acquired the vanA gene cluster from an E. faecium isolate in another case (Weigel et al., 2007).

Recently, a novel mechanism of in vitro resistance to glycopeptide antimicrobials in E. faecium has been described (Cremniter et al., 2006). The E. faecium laboratory mutant strain with the novel resistance mechanism to β-lactam antibiotics (see last paragraph of ‘Ampicillin resistance’) also appeared to be resistant to glycopeptides, while the activation of the ld-transpeptidation pathway can also release inhibition of transglycosylation, leading to cross-resistance to glycopeptides and β-lactams (Cremniter et al., 2006).

Clinical epidemiology of ampicillin and VRE

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

In the US, the first reports on an increase of infections and outbreaks due to ampicillin-resistant E. faecium (AREfm) were published in the early 1980s (Coudron et al., 1984; Murray, 1990; Grayson et al., 1991; Jones et al., 1995). In several European countries, a similar increase of AREfm has been observed, but with a 10-year delay (Lavery et al., 1997; Dornbusch et al., 1998; Fontana et al., 1998; Suppola et al., 1999; Torell et al., 1999; Harthug et al., 2002; Top et al., 2007).

Although the first clinical VRE were detected in Europe, a remarkable difference exists in the epidemiology of VRE between Europe and the United States. In the United States, colonization of hospitalized patients with VRE rapidly increased in the 1990s, up to the current endemic levels in many hospitals. In parallel, nosocomial VRE infection rates increased as well, while colonization in healthy people appeared to be absent. In Europe, the prevalence rates in hospitals have remained much lower and only started to increase since the year 2000 (Schouten et al., 2000; EARSS, 2004). In The Netherlands, outbreaks due to vancomycin-resistant E. faecium (VREF) have been reported in three different hospitals. In all cases, intervention measurements were successful in controlling the outbreak (van der Steen et al., 2000; Timmers et al., 2002; Mascini et al., 2006). It has been suggested that the rapid increase of VRE in the United States was due to a 5–10-fold higher use of vancomycin in the United States compared with five European countries, including France, Italy, Germany, United Kingdom and The Netherlands, which have, in total, a similar number of inhabitants (Kirst et al., 1998; Bonten et al., 2001).

In contrast to the United States, where VRE is restricted to hospitals, a large community reservoir of VRE among healthy people and farm animals exists in Europe, which is most probably linked to massive use of avoparcin in animal husbandry (Van Belkum et al., 1996; Van der Auwera et al., 1996; van den Bogaard et al., 1997a, b, 2002; van den Braak et al., 1998; Stobberingh et al., 1999). Avoparcin is a glycopeptide antimicrobial, like vancomycin, and has been used as a growth promoter in the agricultural industry since the 1970s in most European countries. Because the presence of a large community reservoir of VRE was thought to pose a threat for VRE transmission into hospitals either by enterococcal strains harboring the vancomycin resistance genes or by horizontal transfer of plasmids containing Tn1546 from animal strains to human strains, the European Union banned the use of avoparcin in April 1997. Since then, the prevalence rates of VRE colonization among farm animals and human volunteers have decreased (Klare et al., 1999; van den Bogaard et al., 2000; Aarestrup et al., 2001), although several countries report persistence of VRE, especially in poultry, 3–8 years after the ban (Borgen et al., 2000a, b, 2001; Heuer et al., 2002; Manson et al., 2004; Johnsen et al., 2005; Sorum et al., 2006).

Methods to study the genetic relatedness of E. faecium

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

Molecular typing methods are essential to determine, in detail, the epidemiology of E. faecium and its resistance traits, and to identify outbreaks in hospitals. Furthermore, the recognized presence of E. faecium in different ecological niches created an additional need to determine its population structure and genetic evolution.

The first molecular typing methods used for enterococci were based on the analysis of plasmid profiles, including plasmid composition and restriction endonuclease analysis of specific plasmids (Luginbuhl et al., 1987; Zervos et al., 1987). In the late 1980s, a new typing method was developed based on analysis of chromosomal DNA restriction endonuclease profiles by pulsed-field gel electrophoresis (PFGE) (Chu et al., 1986), which was soon adapted for enterococci (Murray et al., 1990; Goering & Winters, 1992). Until recently, many laboratories considered PFGE to be the ‘Gold Standard’ typing method. However, in the literature, there is inconsistency about the stability of DNA banding patterns of enterococci (Bonten et al., 1998; Morrison et al., 1999; Werner et al., 2003b) and therefore PFGE is suitable for the purpose of tracing transmission of strains that are associated in time and location, but not for long-term epidemiological studies. For several bacterial species, an international database, designated PulseNet, was developed with standardized protocols, aimed at early recognition of outbreaks of foodborne diseases (Swaminathan et al., 2001, 2006), but for enterococci interlaboratory data exchange is still problematic as there is a lack of standardized conditions for electrophoresis and criteria for interpreting PFGE banding patterns (Tenover et al., 1995; Kim et al., 1999; Morrison et al., 1999; Facklam et al., 2002).

To study the genetic relatedness between epidemiologically nonrelated VREF, amplified-fragment length polymorphism analysis (AFLP) was developed, which allows analysis of polymorphisms among small restriction fragments (Willems et al., 2000). With this technique, particular E. faecium genogroups appeared to be associated with particular hosts, like pigs, calves, poultry and humans. Most importantly, though, there were genetic differences between VREF isolated from feces of nonhospitalized persons without infection (genogroup A) and isolates from hospitalized patients of fecal origin or from infected body sites like blood (genogroup C). Other studies confirmed the existence of these genogroups among vancomycin-susceptible E. faecium (VSEF) isolates originating from different sources (Borgen et al., 2002; Bruinsma et al., 2002; Jureen et al., 2003, 2004; Coque et al., 2005). Furthermore, AFLP exhibited a discriminatory power comparable to PFGE and discriminated outbreak-related isolates from other isolates (Jureen et al., 2004).

Although AFLP appeared to be a robust and fast typing method generating reproducible data within a given laboratory, this method was less suitable for data exchange between different laboratories and for studying the global epidemiology and the evolution of E. faecium. For this, a typing method is required, that generates unambiguous data suitable for the development of web-based databases. In 1998, multi locus sequence typing (MLST) was proposed for Neisseria meningitides with the afore mentioned properties (Maiden et al., 1998). MLST is based on identifying alleles from DNA sequences of internal fragments of housekeeping genes, resulting in a numeric allelic profile. Each profile is assigned a sequence type (ST). In addition, an Internet site with the possibility for data exchange was developed (http://www.mlst.net), which, currently, together with http://www.pubMLST.org, contains MLST schemes of 38 different bacterial species, including E. faecium (Homan et al., 2002) and E. faecalis (Ruiz-Garbajosa et al., 2006). MLST of 123 isolates, including VREF and VSEF originating from human (nonhospitalized, clinical and hospital outbreak) and animal sources from various countries, confirmed the genogroups as determined by AFLP, including the hospital-related genogroup C (Homan et al., 2002). MLST typing of the hospital-related isolates revealed that the outbreak isolates clustered in a sub-population designated lineage C1, which was subsequently confirmed in many studies performed world wide (Werner et al., 2003a; Bonora et al., 2004; Coque et al., 2005; Ko et al., 2005; Lee et al., 2006).

In a more recent study, MLST analysis of 411 E. faecium isolates, including VREF and VSEF from different human and animal sources and different continents, explored the evolutionary origin of epidemic isolates by discerning patterns of microevolution within the C1 lineage and determined the population structure of E. faecium (Willems et al., 2005). ST17 is the predicted founder of the C1 lineage and therefore this genetic subpopulation is renamed in clonal complex-17 (CC17), which is characterized by ampicillin and quinolone resistance.

The recognition of CC17 as a hospital-adapted E. faecium subpopulation, responsible for the majority of the hospital burden, created a need for rapid typing of E. faecium, in order to better target infection control measures in hospitals. With this purpose, a multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA) typing scheme has been developed (Top et al., 2004). MLVA is based on variation in six, over the genome dispersed, VNTR loci of E. faecium. For each VNTR locus, the number of repeats is determined by PCR using primers based on the conserved flanking regions of the tandem repeats. PCR products are separated on agarose gels and the band size determines the number of repeats. The six numbers together result in the MLVA profile and each profile is assigned an MLVA type (MT). An internet site has been developed (http://www.mlva.umcutrecht.nl) to serve as a database and also for the submission of MLVA profiles to assign MTs. The MLVA scheme was validated by typing 291 E. faecium isolates both with MLVA and with MLST. The discriminatory power of both methods was comparable, but more importantly certain MLVA profiles were predictive of whether isolates will belong to the MLST-based subpopulation CC17 with a sensitivity of 97% and a specificity of 90% (Top et al., 2004).

Molecular characterization of DNA heterogeneity in the vanA gene cluster of Tn1546 in isolates from humans and animals revealed high degrees of DNA polymorphisms due to point mutations, deletions and insertions of different insertion sequences e.g. IS1216 V and IS1251, which can be used to study the epidemiology of Tn1546 (Willems et al., 1999; Schouten et al., 2001). Identical Tn1546 variants among VREF recovered from farm animals and humans were identified, which could be a result of either colonization of animal-derived VREF in humans or transfer of Tn1546 from animal VREF to human enterococcal isolates (Jensen et al., 1998; van den Braak et al., 1998; Woodford et al., 1998; Descheemaeker et al., 1999). Combining molecular typing data of isolates and the vanA transposon has improved our insights into the transmission of vancomycin resistance between different ecological niches (Jensen et al., 2003).

Virulence determinants in E. faecium

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

In contrast to E. faecalis, little is known about the virulence of E. faecium (Gilmore et al., 2002). Many clinical isolates of E. faecium are resistant to phagocytosis by neutrophils (Arduino et al., 1994), which might be considered to be a pathogenic property.

Other putative virulence factors are the secreted antigen SagA (Teng et al., 2003) and a surface-exposed antigen designated Acm (Nallapareddy et al., 2003). Both antigens are able to bind to human extracellular matrix proteins. In contrast to the specific collagen-binding adhesin Acm, SagA has broad-spectrum binding to fibrinogen, collagen type I, collagen type IV, fibronectin and laminin. Although the exact role of both antigens in the pathogenesis of E. faecium infections is not well understood, adherence to extracellular matrix proteins might be the first step in colonization of the host.

In Caenorhabditis elegans, E. faecium produces hydrogen peroxide at levels that cause cellular damage (Moy et al., 2004). Additional studies are necessary to investigate the relevance of hydrogen peroxide production by E. faecium in the human host.

Gelatinase is an extracellular zinc mettaloprotease, which contributes to E. faecalis virulence in some animal models and is regulated in a cell-density-dependent manner by the fsr operon (Qin et al., 2000, 2001). Recently, dissemination of gelatinase was also described in E. faecium (Lopes et al., 2006).

The identification of the E. faecium subpopulation CC17 raised the question of whether this population contained specific traits, which contribute to increased abilities in spread and/or infections among hospitalized patients. Screening of human and animal isolates for the presence of the esp gene, which has been associated with increased virulence and biofilm formation in E. faecalis (Shankar et al., 1999, 2001; Toledo-Arana et al., 2001; Tendolkar et al., 2004, 2005), revealed that in E. faecium the esp gene is restricted to hospital-derived isolates belonging to the CC17 (Baldassarri et al., 2001; Bonten et al., 2001; Willems et al., 2001; Eaton & Gasson, 2001, 2002; Coque et al., 2002; Hammerum & Jensen, 2002). Interestingly, in E. faecalis this gene is contained on a pathogenicity island (Shankar et al., 2002) and was identified among clinical and animal-derived isolates (Shankar et al., 1999; Hammerum & Jensen, 2002; Dupre et al., 2003; Creti et al., 2004). Analysis of the up- and downstream regions of the E. faecium esp revealed that as in E. faecalis, the esp gene in E. faecium is contained on a putative pathogenicity island, which is different from the E. faecalis pathogenicity island (Leavis et al., 2004). In E. faecium, Esp expression on the surface was shown to be growth condition dependent and Esp is involved in initial adherence and biofilm formation (van Wamel et al., 2007). Recently, the role of Esp in biofilm formation was confirmed by a biofilm deficient esp insertion-deletion mutant (Heikens et al., 2007), which was constructed using a temperature-sensitive vector (Nallapareddy et al., 2006).

In 2003, another putative virulence gene, hyaluronidase (hylEfm), with homology to the same gene in Streptococcus pyogenes and Streptococcus pneumoniae, was described to be enriched among clinical E. faecium isolates (Rice et al., 2003). Although the presumed function of hyaluronidase in E. faecium is still unknown, in S. pneumoniae it is suggested that hyaluronidase may contribute to the invasion of the nasopharynx.

Concluding remarks

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References

The rapid increase of infections and outbreaks with VRE in the United States was preceded by an increase of infections and outbreaks with AREfm. In Europe, a similar increase can be observed but with a 10-year delay. Recent molecular epidemiological studies revealed that this worldwide emergence is due to a specific E. faecium subpopulation CC17, which is characterized by ampicillin and quinolone resistance. Furthermore, the majority of the CC17 isolates contain a putative pathogenicity island, including the esp gene, and another putative virulence gene hylEfm was found to be enriched among clinical isolates. All these findings suggest that E. faecium ST17, the predicted founder of CC17, has been able to adapt to the hospital environment in a multi step process, in which ST17 isolates first acquired ampicillin resistance, and by cumulative acquisition of adaptive elements, like resistance genes and putative virulence genes, ST17 gained selective advantage. This was followed by an increase in frequency facilitating further adaptive possibilities and genetic diversification, resulting in a complex of closely-related genotypes (CC17) (Willems et al., 2005). This process has been called genetic capitalism (Baquero et al., 2003). Interestingly, mixed whole-genome microarray analysis based on comparative genome hybridization of 97 E. faecium strains isolated from different epidemiological niches worldwide revealed a hospital clade, that largely overlapped with the MLST-based CC17 subpopulation (Leavis et al., 2007). Furthermore, the whole-genome analysis revealed over hundred hospital-clade specific genes, including mobile elements like insertion sequence (IS) elements, phage genes and plasmid sequences, hypothetical and membrane proteins and antibiotic resistance and regulatory genes (Leavis et al., 2007).

With the development of new molecular tools, construction of isogenic mutants of e.g. virulence genes in E. faecium will help to investigate the role of these genes in the pathogenesis of E. faecium. This knowledge may lead to the development of novel intervention strategies to prevent infections and spread of CC17 E. faecium.

References

  1. Top of page
  2. Abstract
  3. General
  4. Antimicrobial resistance in enterococci
  5. Ampicillin resistance
  6. Glycopeptide resistance
  7. Clinical epidemiology of ampicillin and VRE
  8. Methods to study the genetic relatedness of E. faecium
  9. Virulence determinants in E. faecium
  10. Concluding remarks
  11. References
  • Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS & Bager F (2001) Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 45: 20542059.
  • Al Obeid S, Gutmann L & Williamson R (1990) Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci. J Antimicrob Chemother 26: 613618.
  • Appelbaum PC (2006) The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 12 (suppl 1), 1623.
  • Arduino RC, Jacques-Palaz K, Murray BE & Rakita RM (1994) Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis. Infect Immun 62: 55875594.
  • Arthur M, Molinas C, Depardieu F & Courvalin P (1993) Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 175: 117127.
  • Arthur M, Reynolds P & Courvalin P (1996) Glycopeptide resistance in enterococci. Trends Microbiol 4: 401407.
  • Baldassarri L, Bertuccini L, Ammendolia MG, Gherardi G & Creti R (2001) Variant esp gene in vancomycin-sensitive Enterococcus faecium. Lancet 357: 1802.
  • Baquero F, Coque TM & Canton R (2003) Antibiotics, complexity, and evolution. ASM News 69: 547552.
  • Barna JC & Williams DH (1984) The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 38: 339357.
  • Bonora MG, Ligozzi M, De Fatima M, Bragagnolo L, Goglio A, Guazzotti GC & Fontana R (2004) Vancomycin-resistant Enterococcus faecium isolates causing hospital outbreaks in northern Italy belong to the multilocus sequence typing C1 lineage. Microb Drug Resist 10: 114123.
  • Bonten MJ, Hayden MK, Nathan C, Rice TW & Weinstein RA (1998) Stability of vancomycin-resistant enterococcal genotypes isolated from long-term-colonized patients. J Infect Dis 177: 378382.
  • Bonten MJ, Willems R & Weinstein RA (2001) Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 1: 314325.
  • Borgen K, Simonsen GS, Sundsfjord A, Wasteson Y, Olsvik O & Kruse H (2000a) Continuing high prevalence of VanA-type vancomycin-resistant enterococci on Norwegian poultry farms three years after avoparcin was banned. J Appl Microbiol 89: 478485.
  • Borgen K, Sorum M, Kruse H & Wasteson Y (2000b) Persistence of vancomycin-resistant enterococci (VRE) on Norwegian broiler farms. FEMS Microbiol Lett 191: 255258.
  • Borgen K, Sorum M, Wasteson Y & Kruse H (2001) VanA-type vancomycin-resistant enterococci (VRE) remain prevalent in poultry carcasses 3 years after avoparcin was banned. Int J Food Microbiol 64: 8994.
  • Borgen K, Wasteson Y, Kruse H & Willems RJ (2002) Vancomycin-resistant Enterococcus faecium (VREF) from Norwegian poultry cluster with VREF from poultry from the United Kingdom and the Netherlands in an amplified fragment length polymorphism genogroup. Appl Environ Microbiol 68: 31333137.
  • Bradley CR & Fraise AP (1996) Heat and chemical resistance of enterococci. J Hosp Infect 34: 191196.
  • Brisson-Noel A, Dutka-Malen S, Molinas C, Leclercq R & Courvalin P (1990) Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147. Antimicrob Agents Chemother 34: 924927.
  • Bruinsma N, Willems RJ, Van Den Bogaard AE, Santen-Verheuvel M, London N, Driessen C & Stobberingh EE (2002) Different levels of genetic homogeneity in vancomycin-resistant and -susceptible Enterococcus faecium isolates from different human and animal sources analyzed by amplified-fragment length polymorphism. Antimicrob Agents Chemother 46: 27792783.
  • Carias LL, Rudin SD, Donskey CJ & Rice LB (1998) Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 180: 44264434.
  • Chang S, Sievert DM, Hageman JC et al. (2003) Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348: 13421347.
  • Chu G, Vollrath D & Davis RW (1986) Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science 234: 15821585.
  • Coque TM, Tomayko JF, Ricke SC, Okhyusen PC & Murray BE (1996) Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 40: 26052609.
  • Coque TM, Willems R, Canton R, Del Campo R & Baquero F (2002) High occurrence of esp among ampicillin-resistant and vancomycin-susceptible Enterococcus faecium clones from hospitalized patients. J Antimicrob Chemother 50: 10351038.
  • Coque TM, Willems RJ, Fortun J, Top J, Diz S, Loza E, Canton R & Baquero F (2005) Population structure of Enterococcus faecium causing bacteremia in a Spanish university hospital: setting the scene for a future increase in vancomycin resistance? Antimicrob Agents Chemother 49: 26932700.
  • Costa Y, Galimand M, Leclercq R, Duval J & Courvalin P (1993) Characterization of the chromosomal aac(6)-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 37: 18961903.
  • Coudron PE, Mayhall CG, Facklam RR, Spadora AC, Lamb VA, Lybrand MR & Dalton HP (1984) Streptococcus faecium outbreak in a neonatal intensive care unit. J Clin Microbiol 20: 10441048.
  • Courvalin P (2006) Vancomycin resistance in gram-positive cocci. Clin Infect Dis 42: S25S34.
  • Cremniter J, Mainardi JL, Josseaume N, Quincampoix JC, Dubost L, Hugonnet JE, Marie A, Gutmann L, Rice LB & Arthur M (2006) Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium. J Biol Chem 281: 3225432262.
  • Creti R, Imperi M, Bertuccini L, Fabretti F, Orefici G, Di Rosa R & Baldassarri L (2004) Survey for virulence determinants among Enterococcus faecalis isolated from different sources. J Med Microbiol 53: 1320.
  • Dahl KH, Simonsen GS, Olsvik O & Sundsfjord A (1999) Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci. Antimicrob Agents Chemother 43: 11051110.
  • Dahl KH, Lundblad EW, Rokenes TP, Olsvik O & Sundsfjord A (2000) Genetic linkage of the vanB2 gene cluster to Tn5382 in vancomycin-resistant enterococci and characterization of two novel insertion sequences. Microbiology 146: 14691479.
  • Descheemaeker PR, Chapelle S, Devriese LA, Butaye P, Vandamme P & Goossens H (1999) Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother 43: 20322037.
  • Dornbusch K, King A & Legakis N (1998) Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 30: 281288.
  • Dupre I, Zanetti S, Schito AM, Fadda G & Sechi LA (2003) Incidence of virulence determinants in clinical Enterococcus faecium and Enterococcus faecalis isolates collected in Sardinia (Italy). J Med Microbiol 52: 491498.
  • EARSS (2004) European Antimicrobial Resistance Surveillance System Annual report 2004 (http://www.earss.rivm.nl).
  • Eaton TJ & Gasson MJ (2001) Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl Environ Microbiol 67: 16281635.
  • Eaton TJ & Gasson MJ (2002) A variant enterococcal surface protein Esp(fm) in Enterococcus faecium; distribution among food, commensal, medical, and environmental isolates. FEMS Microbiol Lett 216: 269275.
  • Facklam RR & Collins MD (1989) Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 27: 731734.
  • Facklam RR, Carvalho MG & Teixeira LM (2002) Biochemical Characteristics and Antibiotic Susceptibility Testing of Enterococci. The Enterococci; Pathogenesis, Molecular Biology and Antibiotic Resistance (GilmoreMS, ed), pp. 154. ASM Press, Washington.
  • Fontana R, Amalfitano G, Rossi L & Satta G (1992) Mechanisms of resistance to growth inhibition and killing by beta-lactam antibiotics in enterococci. Clin Infect Dis 15: 486489.
  • Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A & Satta G (1994) Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 38: 19801983.
  • Fontana R, Ligozzi M, Mazzariol A, Veneri G & Cornaglia G (1998) Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance. Clin Infect Dis 27: S84S86.
  • Fortun J, Coque TM, Martin-Davila P, Moreno L, Canton R, Loza E, Baquero F & Moreno S (2002) Risk factors associated with ampicillin resistance in patients with bacteraemia caused by Enterococcus faecium. J Antimicrob Chemother 50: 10031009.
  • Freeman R, Kearns AM & Lightfoot NF (1994) Heat resistance of nosocomial enterococci. Lancet 344: 6465.
  • Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, Eisner W, Warren S & Kreiswirth B (1993) Emergence of vancomycin-resistant enterococci in New York City. Lancet 342: 7679.
  • Georgopapadakou NH & Liu FY (1980) Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity. Antimicrob Agents Chemother 18: 834836.
  • Gilmore MS, Coburn PS, Nallapareddy SR & Murray BE (2002) Enterococcal Virulence. The Enterococci; Pathogenesis, Molecular Biology and Antibiotic Resistance (GilmoreMS, ed), pp. 301354. ASM Press, Washington.
  • Goering RV & Winters MA (1992) Rapid method for epidemiological evaluation of gram-positive cocci by field inversion gel electrophoresis. J Clin Microbiol 30: 577580.
  • Gordon S, Swenson JM, Hill BC, Pigott NE, Facklam RR, Cooksey RC, Thornsberry C, Jarvis WR & Tenover FC (1992) Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol 30: 23732378.
  • Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ & Moellering RC Jr (1991) Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 35: 21802184.
  • Guru P (1993) Nosocomial enterococci resistant to vancomycin – United States, 1989–1993. Morb Mortal Wkly Rep 42: 597599.
  • Guru P (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470485.
  • Hammerum AM & Jensen LB (2002) Prevalence of esp, encoding the enterococcal surface protein, in Enterococcus faecalis and Enterococcus faecium isolates from hospital patients, poultry, and pigs in Denmark. J Clin Microbiol 40: 4396.
  • Harthug S, Jureen R, Mohn SC, Digranes A, Simonsen GS, Sundsfjord A & Langeland N (2002) The prevalence of faecal carriage of ampicillin-resistant and high-level gentamicin-resistant enterococci among inpatients at 10 major Norwegian hospitals. J Hosp Infect 50: 145154.
  • Heikens E, Bonten MJ & Willems RJ (2007) Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol 189: 82338240.
  • Heuer OE, Pedersen K, Jensen LB, Madsen M & Olsen JE (2002) Persistence of vancomycin-resistant enterococci (VRE) in broiler houses after the avoparcin ban. Microb Drug Resist 8: 355361.
  • Homan WL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, Van Embden JD & Willems RJ (2002) Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol 40: 19631971.
  • Jensen LB, Ahrens P, Dons L, Jones RN, Hammerum AM & Aarestrup FM (1998) Molecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humans. J Clin Microbiol 36: 437442.
  • Jensen LB, Willems RJ & Van Den Bogaard AE (2003) Genetic characterization of glycopeptide-resistant enterococci of human and animal origin from mixed pig and poultry farms. APMIS 111: 669672.
  • Johnsen PJ, Osterhus JI, Sletvold H, Sorum M, Kruse H, Nielsen K, Simonsen GS & Sundsfjord A (2005) Persistence of animal and human glycopeptide-resistant enterococci on two Norwegian poultry farms formerly exposed to avoparcin is associated with a widespread plasmid-mediated vanA element within a polyclonal Enterococcus faecium population. Appl Environ Microbiol 71: 159168.
  • Jones RN, Sader HS, Erwin ME & Anderson SC (1995) Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis 21: 8593.
  • Jureen R, Top J, Mohn SC, Harthug S, Langeland N & Willems RJ (2003) Molecular characterization of ampicillin-resistant Enterococcus faecium isolates from hospitalized patients in Norway. J Clin Microbiol 41: 23302336.
  • Jureen R, Harthug S, Sornes S, Digranes A, Willems RJ & Langeland N (2004) Comparative analysis of amplified fragment length polymorphism and pulsed field gel electrophoresis in a hospital outbreak and subsequent endemicity of ampicillin-resistant Enterococcus faecium. FEMS Immunol Med Microbiol 40: 3339.
  • Kak V & Chow JW (2002) Acquired antibiotic resistance in Enterococci. The Enterococci; Pathogenesis, Molecular Biology and Antibiotic Resistance (GilmoreMS, ed), pp. 355383. ASM Press, Washington.
  • Kearns AM, Freeman R & Lightfoot NF (1995) Nosocomial enterococci: resistance to heat and sodium hypochlorite. J Hosp Infect 30: 193199.
  • Kim WJ, Weinstein RA & Hayden MK (1999) The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 179: 163171.
  • Kirst HA, Thompson DG & Nicas TI (1998) Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42: 13031304.
  • Klare I, Rodloff AC, Wagner J, Witte W & Hakenbeck R (1992) Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 36: 783787.
  • Klare I, Badstubner D, Konstabel C, Bohme G, Claus H & Witte W (1999) Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. Microb Drug Resist 5: 4552.
  • Klare I, Konstabel C, Mueller-Bertling S et al. (2005) Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Infect Dis 24: 815825.
  • Ko KS, Baek JY, Lee JY, Oh WS, Peck KR, Lee N, Lee WG, Lee K & Song JH (2005) Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from Korea. J Clin Microbiol 43: 23032306.
  • Lavery A, Rossney AS, Morrison D, Power A & Keane CT (1997) Incidence and detection of multi-drug-resistant enterococci in Dublin hospitals. J Med Microbiol 46: 150156.
  • Leavis H, Top J, Shankar N, Borgen K, Bonten M, Van Embden J & Willems RJ (2004) A novel putative enterococcal pathogenicity island linked to the esp virulence gene of Enterococcus faecium and associated with epidemicity. J Bacteriol 186: 672682.
  • Leavis HL, Willems RJ, Van Wamel WJ, Schuren FH, Caspers MP & Bonten MJ (2007) Insertion sequence-driven diversification creates a globally dispersed emerging multiresistant subspecies of E. faecium. PLoS Pathog 3: e7.
  • Leclercq R, Derlot E, Duval J & Courvalin P (1988) Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319: 157161.
  • Lee WG, Lee SM & Kim YS (2006) Molecular characterization of Enterococcus faecium isolated from hospitalized patients in Korea. Lett Appl Microbiol 43: 274279.
  • Ligozzi M, Pittaluga F & Fontana R (1996) Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 40: 354357.
  • Lopes MF, Simoes AP, Tenreiro R, Marques JJ & Crespo MT (2006) Activity and expression of a virulence factor, gelatinase, in dairy enterococci. Int J Food Microbiol 112: 208214.
  • Low DE, Keller N, Barth A & Jones RN (2001) Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 32: S133S145.
  • Luginbuhl LM, Rotbart HA, Facklam RR, Roe MH & Elliot JA (1987) Neonatal enterococcal sepsis: case-control study and description of an outbreak. Pediatr Infect Dis J 6: 10221026.
  • Maiden MC, Bygraves JA, Feil E et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95: 31403145.
  • Mainardi JL, Legrand R, Arthur M, Schoot B, Van Heijenoort J & Gutmann L (2000) Novel mechanism of beta-lactam resistance due to bypass of dd-transpeptidation in Enterococcus faecium. J Biol Chem 275: 1649016496.
  • Mainardi JL, Morel V, Fourgeaud M, Cremniter J, Blanot D, Legrand R, Frehel C, Arthur M, Van Heijenoort J & Gutmann L (2002) Balance between two transpeptidation mechanisms determines the expression of beta-lactam resistance in Enterococcus faecium. J Biol Chem 277: 3580135807.
  • Manson JM, Smith JM & Cook GM (2004) Persistence of vancomycin-resistant enterococci in New Zealand broilers after discontinuation of avoparcin use. Appl Environ Microbiol 70: 57645768.
  • Mascini EM, Troelstra A, Beitsma M et al. (2006) Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 42: 739746.
  • Moellering RC Jr & Weinberg AN (1971) Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest 50: 25802584.
  • Morrison D, Woodford N, Barrett SP, Sisson P & Cookson BD (1999) DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium and criteria for defining strains. J Clin Microbiol 37: 10841091.
  • Moy TI, Mylonakis E, Calderwood SB & Ausubel FM (2004) Cytotoxicity of hydrogen peroxide produced by Enterococcus faecium. Infect Immun 72: 45124520.
  • Mundy LM, Sahm DF & Gilmore M (2000) Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev 13: 513522.
  • Murray BE (1990) The life and times of the Enterococcus. Clin Microbiol Rev 3: 4665.
  • Murray BE (2000) Vancomycin-resistant enterococcal infections. N Engl J Med 342: 710721.
  • Murray BE, Church DA, Wanger A, Zscheck K, Levison ME, Ingerman MJ, Abrutyn E & Mederski-Samoraj B (1986) Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother 30: 861864.
  • Murray BE, An FY & Clewell DB (1988) Plasmids and pheromone response of the beta-lactamase producer Streptococcus (Enterococcus) faecalis HH22. Antimicrob Agents Chemother 32: 547551.
  • Murray BE, Singh KV, Heath JD, Sharma BR & Weinstock GM (1990) Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol 28: 20592063.
  • Nallapareddy SR, Weinstock GM & Murray BE (2003) Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol 47: 17331747.
  • Nallapareddy SR, Singh KV & Murray BE (2006) Construction of improved temperature-sensitive and mobilizable vectors and their use for constructing mutations in the adhesin-encoding acm gene of poorly transformable clinical Enterococcus faecium strains. Appl Environ Microbiol 72: 334345.
  • Neu HC (1987) Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams. Curr Clin Top Infect Dis 8: 3761.
  • Noble CJ (1978) Carriage of group D streptococci in the human bowel. J Clin Pathol 31: 11821186.
  • Oppenheim BA (1998) The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41 (suppl D), 711.
  • Patel R, Uhl JR, Kohner P, Hopkins MK, Steckelberg JM, Kline B & Cockerill FR III (1998) DNA sequence variation within vanA, vanB, vanC-1, and vanC-2/3 genes of clinical Enterococcus isolates. Antimicrob Agents Chemother 42: 202205.
  • Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J & Lyons RW (1995) An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 74: 191200.
  • Qin X, Singh KV, Weinstock GM & Murray BE (2000) Effects of Enterococcus faecalisfsr genes on production of gelatinase and a serine protease and virulence. Infect Immun 68: 25792586.
  • Qin X, Singh KV, Weinstock GM & Murray BE (2001) Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J Bacteriol 183: 33723382.
  • Quintiliani R Jr, Evers S & Courvalin P (1993) The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 167: 12201223.
  • Reynolds PE (1989) Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8: 943950.
  • Reynolds PE & Courvalin P (2005) Vancomycin resistance in enterococci due to synthesis of precursors terminating in d-alanyl-d-serine. Antimicrob Agents Chemother 49: 2125.
  • Rice LB (2006) Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 34: S11S19.
  • Rice LB, Carias L, Rudin S, Vael C, Goossens H, Konstabel C, Klare I, Nallapareddy SR, Huang W & Murray BE (2003) A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 187: 508512.
  • Ruiz-Garbajosa P, Bonten MJ, Robinson DA et al. (2006) Multilocus sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol 44: 22202228.
  • Ruoff KL, De La ML, Murtagh MJ, Spargo JD & Ferraro MJ (1990) Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 28: 435437.
  • Rybkine T, Mainardi JL, Sougakoff W, Collatz E & Gutmann L (1998) Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 178: 159163.
  • Sahm DF, Marsilio MK & Piazza G (1999) Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database – USA. Clin Infect Dis 29: 259263.
  • Schouten MA, Hoogkamp-Korstanje JA, Meis JF & Voss A (2000) Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 19: 816822.
  • Schouten MA, Willems RJ, Kraak WA, Top J, Hoogkamp-Korstanje JA & Voss A (2001) Molecular analysis of Tn1546-like elements in vancomycin-resistant enterococci isolated from patients in Europe shows geographic transposon type clustering. Antimicrob Agents Chemother 45: 986989.
  • Sghir A, Gramet G, Suau A, Rochet V, Pochart P & Dore J (2000) Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 66: 22632266.
  • Shankar V, Baghdayan AS, Huycke MM, Lindahl G & Gilmore MS (1999) Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect Immun 67: 193200.
  • Shankar N, Lockatell CV, Baghdayan AS, Drachenberg C, Gilmore MS & Johnson DE (2001) Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect Immun 69: 43664372.
  • Shankar N, Baghdayan AS & Gilmore MS (2002) Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis. Nature 417: 746750.
  • Simonsen GS, Smabrekke L, Monnet DL et al. (2003) Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother 51: 323331.
  • Sorum M, Johnsen PJ, Aasnes B, Rosvoll T, Kruse H, Sundsfjord A & Simonsen GS (2006) Prevalence, persistence, and molecular characterization of glycopeptide-resistant enterococci in Norwegian poultry and poultry farmers 3 to 8 years after the ban on avoparcin. Appl Environ Microbiol 72: 516521.
  • Stobberingh E, Van Den BA, London N, Driessen C, Top J & Willems R (1999) Enterococci with glycopeptide resistance in turkeys, turkey farmers, turkey slaughterers, and (sub)urban residents in the south of the Netherlands: evidence for transmission of vancomycin resistance from animals to humans? Antimicrob Agents Chemother 43: 22152221.
  • Suppola JP, Kolho E, Salmenlinna S, Tarkka E, Vuopio-Varkila J & Vaara M (1999) vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality. J Clin Microbiol 37: 39343939.
  • Swaminathan B, Barrett TJ, Hunter SB & Tauxe RV (2001) PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg Infect Dis 7: 382389.
  • Swaminathan B, Gerner-Smidt P, Ng LK, Lukinmaa S, Kam KM, Rolando S, Gutierrez EP & Binsztein N (2006) Building PulseNet International: an interconnected system of laboratory networks to facilitate timely public health recognition and response to foodborne disease outbreaks and emerging foodborne diseases. Foodborne Pathog Dis 3: 3650.
  • Tankovic J, Mahjoubi F, Courvalin P, Duval J & Leclerco R (1996) Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 40: 25582561.
  • Tendolkar PM, Baghdayan AS, Gilmore MS & Shankar N (2004) Enterococcal surface protein, Esp, enhances biofilm formation by Enterococcus faecalis. Infect Immun 72: 60326039.
  • Tendolkar PM, Baghdayan AS & Shankar N (2005) The N-terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-mediated biofilm enhancement in Enterococcus faecalis. J Bacteriol 187: 62136222.
  • Teng F, Kawalec M, Weinstock GM, Hryniewicz W & Murray BE (2003) An Enterococcus faecium secreted antigen, SagA, exhibits broad-spectrum binding to extracellular matrix proteins and appears essential for E.faecium growth. Infect Immun 71: 50335041.
  • Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH & Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 22332239.
  • Thouverez M & Talon D (2004) Microbiological and epidemiological studies of Enterococcus faecium resistant to amoxycillin in a university hospital in eastern France. Clin Microbiol Infect 10: 441447.
  • Timmers GJ, Van Der Zwet WC, Simoons-Smit IM, Savelkoul PH, Meester HH, Vandenbroucke-Grauls CM & Huijgens PC (2002) Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 116: 826833.
  • Toledo-Arana A, Valle J, Solano C, Arrizubieta MJ, Cucarella C, Lamata M, Amorena B, Leiva J, Penades JR & Lasa I (2001) The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol 67: 45384545.
  • Top J, Schouls LM, Bonten MJ & Willems RJ (2004) Multiple-locus variable-number tandem repeat analysis, a novel typing scheme to study the genetic relatedness and epidemiology of Enterococcus faecium isolates. J Clin Microbiol 42: 45034511.
  • Top J, Willems R, Blok H, De Regt M, Jalink K, Troelstra A, Goorhuis B & Bonten M (2007) Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium. Clin Microbiol Infect 13: 316319.
  • Torell E, Cars O, Olsson-Liljequist B, Hoffman BM, Lindback J & Burman LG (1999) Near absence of vancomycin-resistant enterococci but high carriage rates of quinolone-resistant ampicillin-resistant enterococci among hospitalized patients and nonhospitalized individuals in Sweden. J Clin Microbiol 37: 35093513.
  • Treitman AN, Yarnold PR, Warren J & Noskin GA (2005) Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol 43: 462463.
  • Uttley AH, Collins CH, Naidoo J & George RC (1988) Vancomycin-resistant enterococci. Lancet 1: 5758.
  • Van Belkum A, Van Den BN, Thomassen R, Verbrugh H & Endtz H (1996) Vancomycin-resistant enterococci in cats and dogs. Lancet 348: 10381039.
  • Van Den Bogaard AE, Jensen LB & Stobberingh EE (1997a) Vancomycin-resistant enterococci in turkeys and farmers. N Engl J Med 337: 15581559.
  • Van Den Bogaard AE, Mertens P, London NH & Stobberingh EE (1997b) High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in the Netherlands: is the addition of antibiotics to animal feeds to blame? J Antimicrob Chemother 40: 454456.
  • Van Den Bogaard AE, Bruinsma N & Stobberingh EE (2000) The effect of banning avoparcin on VRE carriage in the Netherlands. J Antimicrob Chemother 46: 146148.
  • Van Den Bogaard AE, Willems R, London N, Top J & Stobberingh EE (2002) Antibiotic resistance of faecal enterococci in poultry, poultry farmers and poultry slaughterers. J Antimicrob Chemother 49: 497505.
  • Van Den Braak N, Van Belkum A, Van Keulen M, Vliegenthart J, Verbrugh HA & Endtz HP (1998) Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in the Netherlands. J Clin Microbiol 36: 19271932.
  • Van der Auwera P, Pensart N, Korten V, Murray BE & Leclercq R (1996) Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 173: 11291136.
  • Van Der Steen LF, Bonten MJ, Van Kregten E, Harssema-Poot JJ, Willems R & Gaillard CA (2000) Vancomycin-resistant Enterococcus faecium outbreak in a nephrology ward. Ned Tijdschr Geneeskd 144: 25682572.
  • Van Wamel WJ, Hendrickx AP, Bonten MJ, Top J, Posthuma G & Willems RJ (2007) Growth condition-dependent Esp expression by Enterococcus faecium affects initial adherence and biofilm formation. Infect Immun 75: 924931.
  • Weaver KE, Rice LB & Churchward G (2002) Plasmids and Transposons. The Enterococci; Pathogenesis, Molecular Biology and Antibiotic Resistance (GilmoreMS, ed), pp. 219264. ASM Press, Washington.
  • Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE & Tenover FC (2003) Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302: 15691571.
  • Weigel LM, Donlan RM, Shin DH et al. (2007) High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 51: 231238.
  • Werner G, Klare I, Spencker FB & Witte W (2003a) Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 52: 113115.
  • Werner G, Willems RJ, Hildebrandt B, Klare I & Witte W (2003b) Influence of transferable genetic determinants on the outcome of typing methods commonly used for Enterococcus faecium. J Clin Microbiol 41: 14991506.
  • Werner G, Dahl KH & Willems RJ (2006) Composite elements encoding antibiotic resistance in Enterococcus faecium and Enterococcus faecalis. Drug resistance in Enterococci (KobayashiN, ed), pp. 157208. Research Signpost, Kerala, India.
  • Willems RJ, Top J, Van Den Braak N, Van Belkum A, Mevius DJ, Hendriks G, Santen-Verheuvel M & Van Embden JD (1999) Molecular diversity and evolutionary relationships of Tn1546-like elements in enterococci from humans and animals. Antimicrob Agents Chemother 43: 483491.
  • Willems RJ, Top J, Van Den Braak N, Van Belkum A, Endtz H, Mevius D, Stobberingh E, Van Den Bogaard AE & Van Embden JD (2000) Host specificity of vancomycin-resistant Enterococcus faecium. J Infect Dis 182: 816823.
  • Willems RJ, Homan W, Top J et al. (2001) Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet 357: 853855.
  • Willems RJ, Top J, Van Santen M, Robinson DA, Coque TM, Baquero F, Grundmann H & Bonten MJ (2005) Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11: 821828.
  • Williamson R, Le Bouguenec C, Gutmann L & Horaud T (1985) One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 131: 19331940.
  • Williamson R, Gutmann L, Horaud T, Delbos F & Acar JF (1986) Use of penicillin-binding proteins for the identification of enterococci. J Gen Microbiol 132: 19291937.
  • Witte W (2004) Glycopeptide resistant Staphylococcus. J Vet Med B Infect Dis Vet Public Health 51: 370373.
  • Witte W, Wirth R & Klare I (1999) Enterococci. Chemotherapy 45: 135145.
  • Woodford N, Adebiyi AM, Palepou MF & Cookson BD (1998) Diversity of VanA glycopeptide resistance elements in enterococci from humans and nonhuman sources. Antimicrob Agents Chemother 42: 502508.
  • Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS & Schaberg DR (1987) Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med 106: 687691.
  • Zorzi W, Zhou XY, Dardenne O, Lamotte J, Raze D, Pierre J, Gutmann L & Coyette J (1996) Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J Bacteriol 178: 49484957.